Join us in two weeks for a virtual investor event featuring key opinion leader (KOL) Lindsay McAlpine MD, Yale University, who will join company management to discuss the unmet need and current treatment landscape for #longCOVID. The discussion will also cover the evidence implicating chronic neuroinflammation in the persistence of long COVID symptoms. Learn more about the event and register here: https://lnkd.in/eBBkZNFx $BIVI #Inflammation #COVID #CovidResearch
BioVie Inc.
生物技术
Carson City，Nevada 2,368 位关注者
Developing innovative therapies for the treatment of neurodegenerative conditions and advanced liver disease.
关于我们
Focusing on Finding Solutions for Healthier Brain, Memory, and Movement. Our neurology strategy is centered at what we understand to be the nexus of biochemistry, cellular energetics, and neuroprotection, enabling us to explore the potential of our pipeline molecules to decrease inflammation, enhance glucose utilization, protect neurons, and facilitate energy transfer within the central nervous system, ultimately leading to improvements in memory and movement, and a healthier brain. Our lead Neuroscience molecule (NE3107) is currently being investigated in human clinical studies to assess its hypothesized impact on both Alzheimer’s and Parkinson’s. Exploring the possibilities of improved outcomes, fewer medical burdens, and more time at home. In our cirrhosis studies, we are working to learn if our exploratory technology can help individuals who have been diagnosed with cirrhosis-related ascites (fluid that builds up inside the abdomen) to be more comfortable, to require fewer or less frequent medical procedures to drain ascites fluid, and to see if the treatment can help people with ascites to live outside of the hospital for longer periods of time. BioVie is currently investigating BIV-201, a novel formulation of terlipressin, in human clinical trials. In BioVie’s studies of BIV-201, the exploratory medication is provided as a continuous infusion formulation delivered by a small, portable pump that the user can wear while engaging in typical tasks and activities at home. For more information about BioVie and our current studies, please visit our website https://bioviepharma.com/
- 网站
-
https://bioviepharma.com/
BioVie Inc.的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 总部
- Carson City，Nevada
- 类型
- 上市公司
- 创立
- 2013
- 领域
- BioTech、Ascites、Liver、Liver Cirrhosis、Cirrhosis、Liver Disease、Alzheimer's、Dementia、Parkinson's、Clinical Research、Clinical Trials、Biotechnology、Scientific Research、Cognitive Decline、Neuroscience、NE3107和Neurodegenerative
地点
-
主要
获取路线
680 W Nye Ln
US，Nevada，Carson City，89703
BioVie Inc.员工
动态
-
At BioVie, we believe that true advancements can happen when bold science is flanked by bold leadership. That’s why we’re thrilled that Kush Saxena will be advising us on our financial strategy and capital markets approach with a key goal in mind – to advance our lead compound bezisterim through clinical studies in #AlzheimersDisease, #ParkinsonsDisease and #LongCOVID. Bezisterim represents a new approach in the fight against these diseases — targeting neuroinflammation and insulin resistance rather than traditional drug targets (such as the amyloid- and tau-pathways in Alzheimer’s). With growing evidence that both neuroinflammation and insulin resistance play a central role in these devastating conditions, we are committed to unlocking new possibilities for patients in need. By adding world-class expertise to scientific innovation, BioVie is positioning itself to redefine what’s possible in neurology. We’re just getting started. #Neuroinflammation #Investing #Finance #Neurodegeneration
CEO at BioVie | Innovations in Neurodegeneration & Aging-Related Disorders | Founder & Chairman at M6P Therapeutics
When my son was diagnosed with #autism at age 2, I dedicated the next two decades to helping build impactful organizations like Autism Speaks, Celebrate the Children, Profectum Foundation, Exceptional Minds, and the Embrace Program at Florida International University. In recent years, I’ve embarked on another deeply personal quest—tackling #Alzheimer’s Disease (AD) and #Parkinson’s Disease (PD). A dear cousin passed away from Parkinson’s, and my dad’s dementia continues to worsen. I’ve long believed that the research community has been constrained by focusing too narrowly on reducing amyloid and tau, while #neuroinflammation is likely the root cause of both AD and PD. This belief drove me to orchestrate BioVie Inc.'s acquisition that brought us bezisterim, a promising treatment in development for AD, PD, and Long Covid. Bezisterim represents a new — non-amyloid, non-tau — approach to confronting AD. I may know science, but I don’t know everything. That’s why I’m incredibly grateful that Kush Saxena is advising me on our approach to finance and capital markets. I’m excited to benefit from his decades of experience creating value in public companies like Mastercard, Getnet, and H&R Block.
-
Our President and CEO, Cuong Do, recently joined New To The Street to discuss upcoming trials of our lead candidate, bezisterim, in #Parkinsons and #longCOVID – including how our approach to modulating neuroinflammation in various central nervous system (CNS) diseases sets us apart from other companies in the space. Other topics included upcoming company milestones and an update on our novel candidate for refractory #ascites. Watch the full interview here: https://lnkd.in/eF9heFPq $BIVI #Neurology #ClinicalTrials #Inflammation
Cuong Do| President & CEO Biovie
https://www.youtube.com/
-
We are joining all individuals impacted by #longCOVID during #LongCOVIDAwarenessWeek to raise awareness and call for expanded investments in treatment and care. We are committed to helping address the neurological symptoms of long COVID in the soon-to-be-initiated ADDRESS-LC trial: https://lnkd.in/evitPWZ8 #LongCOVIDAwareness2025 #5YearsLater
-
-
Our President and CEO, Cuong Do, joined Next Big Story to provide an overview of our pipeline and near-term milestones, including for the upcoming Phase 2 SUNRISE-PD trial of bezisterim in patients with #ParkinsonsDisease. #BIVI
Introduction To BioVie Inc & Its Pipeline With The CEO | NASDAQ: BIVI
https://www.youtube.com/
-
Today we announced an abstract on the design of our planned Phase 2 trial of bezisterim in patients with #longCOVID has been accepted as a poster presentation at the Demystifying Long COVID International Conference 2024. Read our press release to learn more: https://lnkd.in/e-qgjsKC $BIVI #Inflammation #COVIDResearch
-
-
Today we announced that our upcoming Phase 2 trial of bezisterim in #ParkinsonsDisease is fully funded and expected to start in early 2025, with topline results anticipated by late 2025. Read our press release to learn more: https://lnkd.in/dNeNREN7 $BIVI #Inflammation #ParkinsonsResearch
-
-
Today we announced the closing of our previously announced registered direct offering of common stock priced at-the-market under Nasdaq rules. Gross proceeds from the offering are $6,664,500, before deducting placement agent fees and offering expenses. Read our release to learn more: https://lnkd.in/djPwJDST #BIVI
-
-
We have received a notice of allowance for our Japan patent application covering the novel liquid formulation of terlipressin used in BIV201, which has demonstrated room-temperature stability for up to 24 months – representing an important advantage for treating patients with #cirrhosis and #ascites in the home-care setting. We have now secured patents covering our terlipressin liquid formulation in the U.S., India, Japan and Chile, and have patents pending in eight additional markets. Read our release to learn more: https://lnkd.in/e5pQMriS #BIVI #LiverDisease
-
-
We have received a notice of allowance for our U.S. patent application covering the novel liquid formulation of terlipressin used in BIV201, which has demonstrated room-temperature stability for up to 24 months – representing an important advantage for treating patients with #cirrhosis and #ascites in the home-care setting. We have now secured patents covering our terlipressin liquid formulation in the U.S., India and Chile, and have patents pending in nine additional markets. Read our press release to learn more: https://lnkd.in/ep5rzCGw #BIVI #LiverDisease
-